Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
- Glens Falls Hospital — Glens Falls, New York
- Northwell Health Cancer Institute at Huntington — Greenlawn, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in New York: - NYOH Albany Cancer Center — Albany, New York
- Hematology-Oncology Associates of Central New York, PC — Auburn, New York
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists — Babylon, New York
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists — Brooklyn, New York
- Hematology-Oncology Associates of Central New York, PC — Camillus, New York
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in New York: - MSK Commack — Commack, New York
- MSK Westchester — Harrison, New York
- Rockefeller Outpatient Pavilion (53rd Street) — New York, New York
- Memorial Solan Kettering Cancer Center- Main Campus — New York, New York
- MSK Nassau — Uniondale, New York
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in New York: - Clinical Study Site — Mineola, New York
- Clinical Study Site — New York, New York
- Clinical Study Site — Rochester, New York
- Clinical Study Site — Syracuse, New York
- Clinical Study Site — The Bronx, New York
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in New York: - Perlmutter Cancer Center at NYU Long Island — Mineola, New York
- NYU Langone Medical Center NYU Hematology Associates — New York, New York
- New York Cancer and Blood Specialists — Shirley, New York
- Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York
- University of Buffalo Kaleida Health Cancer Care — Williamsville, New York
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — East White Plains, New York
- Mount Sinai Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in New York: - Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — Mineola, New York
- New York Cancer and Blood Specialists — Shirley, New York
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in New York: - Northwell Health Center for Advanced Medicine. /ID# 279590 — Lake Success, New York
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in New York: - NYU Langone Medical Center — New York, New York
- Columbia University Medical Center — New York, New York
Phase 3 Recruiting Academic/Other
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (…
Sponsor: Roswell Park Cancer Institute
NCT ID: NCT06563388
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in New York: - Local Institution - 2117 — New York, New York
- Local Institution - 1002 — New York, New York
- Local Institution - 2102 — New York, New York
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in New York: - Hematology Oncology Associates of Central New York — East Syracuse, New York
- Northwell Health Cancer Institute — Lake Success, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in New York: - Northwell Health / RJ Zuckerberg Cancer Center — Lake Success, New York
- Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center Main Campus — New York, New York
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in New York: - Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in New York: - Memorial Sloan-Kettering Cancer Center — New York, New York
- New York Cancer & Blood Specialists — Shirley, New York
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in New York: - NYU Langone Health Perlmutter Cancer Center — New York, New York
Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Sponsor: Verastem, Inc.
NCT ID: NCT07659795
Sites in New York: - Perlmutter Cancer Center at NYU Langone Health (contact for more locations) — New York, New York
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in New York: - Northwell Health Center for Advanced Medicine. /ID# 275331 — Lake Success, New York
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in New York: - Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Columbia University — New York, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RA…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07397338
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in New York: - NYU Langone Health — New York, New York
- Icahn School of Medicine At Mount Sinai Prime — New York, New York
- Clinical Research Alliance, Inc — Westbury, New York
- White Plains Hospital — White Plains, New York
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in New York: - START New York — Lake Success, New York